Randomized clinically controlled trials (RCTs) and meta-analyses of the results of trials in patients with HF have shown that SGLT2 inhibitors improve cardiovascular outcomes in patients with chronic HF, irrespective of their diabetes status (6). The gene discussed is SLC5A2; the disease is hydrops fetalis.